Breakthrough requests swamp FDA

Share this article:
Breakthrough requests swamp FDA
Breakthrough requests swamp FDA

FDA's drug center says it has been so overwhelmed with industry's response to its new Breakthrough Therapy program that it is becoming difficult to promise an “all hands” commitment.

At a January FDA rare disease workshop in Silver Spring, MD, Richard Moscicki, a deputy director for the agency, said the number of such requests and designations has “exceeded expectations.” As of December, the program had received 121 requests and granted 34 designations, about one third for genetic diseases.

FDA managers have been somewhat disappointed by the number of designation requests for drugs that are late in the development phase; in some cases the marketing application has already been submitted.

“This is not the purpose of the program and requests should be early in development to allow us to work easily with those developing it,” he said.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"